Dai Kubota

Dr. Dai Kubota

The University of Tokyo, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 May 2026 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Open access
KWKenta Watanabe
Kenta Watanabe
SFSho Fukuda
Sho Fukuda
DKDai Kubota
Dai Kubota
NYNobutake Yamamichi
Nobutake Yamamichi
YTYu Takahashi
Yu Takahashi
KIKatsunori Iijima
Katsunori Iijima
Background and Aim: In Japan, gastric cancer (GC) and esophageal squamous cell carcinoma (ESCC) account for nearly all fatal upper gastrointestinal malignancies. A unified model that simultaneously predicts the incidence of these two cancers could help optimize endoscopic screening and postindex surveillance strategies. Methods: We conducted a retrospective multicenter cohort study of 33 422 individuals who underwent screening esophagogastroduodenoscopy (EGD) at 17 health check‐up institutions across Japan. Clinical and endoscopic data from the index EGD were used to develop a 5‐year risk prediction model for GC or ESCC. Significant predictors were identified using Cox regression, and a scoring system (J‐GESS score) was constructed by scaling β coefficients. Model performance was evaluated using the 5‐year inverse probability of censoring weighted (IPCW) Brier score, calibration, and c indices. Internal validation used bootstrap resampling (500 iterations) to obtain optimism‐corrected estimates. Decision curve analysis (DCA) assessed clinical utility at 5 years. Results: At 5 years, the IPCW‐estimated cumulative incidence of GC or ESCC was 0.84% (234 events). Independent predictors included older age, male sex, ever smoking, and endoscopic gastric mucosal atrophy. The model showed good calibration at 5 years (calibration‐in‐the‐large 0.005; slope 1.055; identical after optimism correction) and robust discrimination (Harrell's c index 0.81; Uno's 5‐year c index 0.81). DCA demonstrated positive net benefit across clinically relevant thresholds. Conclusion: Using routinely collected health check‐up data, we developed a unified, practical, and internally validated 5‐year prediction model for GC and ESCC. The J‐GESS score enables effective risk stratification and may inform postindex endoscopic surveillance and screening interval optimization in Japan.

8 September 2022 in Digestion
Verified
Journal Article
Open access
PDF file
DKDai Kubota
Dai Kubota
YTYu Takahashi
Yu Takahashi
NYNobutake Yamamichi
Nobutake Yamamichi
MMMaki Matsui
Maki Matsui
TSTakeshi Shimamoto
Takeshi Shimamoto
MFMitsuhiro Fujishiro
Mitsuhiro Fujishiro
Introduction: Helicobacter pylori eradication is expected to significantly change the prevalence of Barrett’s esophagus (BE). However, few reports on this relationship exist. We analyzed the risk factors of BE using the current consensus on length of BE considering H. pylori infection status. Methods: We analyzed 10,122 individuals (5,962 men; mean age = 52.9 ± 9.9 years) who had undergone esophagogastroduodenoscopy as part of a medical checkup. Correlations among factors including H. pylori infectious status, endoscopic findings, and BE ≥1 cm were analyzed. Results: Prevalence of BE, long-segment BE, and esophageal adenocarcinoma was 22.5%, 0.014%, and 0%, respectively. Logistic regression analysis showed that the risk factors for BE were hiatal hernia (odds ratio [OR]: 2.89 [2.59–3.24]), female sex (OR: 0.52 [0.46–0.59]), social drinking (OR:0.77 [0.68–0.87]), H. pylori eradication therapy (OR: 1.34 [1.19–1.51]), proton pump inhibitor (PPI) use (OR: 1.52 [1.18–1.96]), bile reflux (OR: 1.18 [1.04–1.33]), age ≥50 years (OR: 1.13 [1.02–1.26]), and nonsteroidal anti-inflammatory drug (NSAID) use (OR: 1.29 [1.02–1.62]). Although reflux esophagitis (RE) was more common in H. pylori-negative patients (17.2%) than in those after H. pylori eradication therapy (11.8%, p < 0.00001), the latter was correlated with BE, disputing RE as a strong risk factor for BE. Therefore, we conducted a subgroup analysis; most of the risk factors except for PPI use (p = 0.75), H2-receptor antagonist use (p = 0.078), and atrophic gastritis absence (p = 0.72) were positively correlated with BE after H. pylori eradication therapy compared with H. pylori-negative status. Conclusions: H. pylori eradication, bile reflux, PPI use, and NSAID use were risk factors for BE along with hiatal hernia, male sex, and older age.

4 July 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
HHHiroyuki Hisada
Hiroyuki Hisada
YSYoshiki Sakaguchi
Yoshiki Sakaguchi
KOKaori Oshio
Kaori Oshio
SMSatoru Mizutani
Satoru Mizutani
HNHideki Nakagawa
Hideki Nakagawa
MFMitsuhiro Fujishiro
Mitsuhiro Fujishiro
Although the mortality rates of gastric cancer (GC) are gradually declining, gastric cancer is still the fourth leading cause of cancer-related death worldwide. This may be due to the high rate of patients who are diagnosed with GC at advanced stages. However, in countries such as Japan with endoscopic screening systems, more than half of GCs are discovered at an early stage, enabling endoscopic resection (ER). Especially after the introduction of endoscopic submucosal dissection (ESD) in Japan around 2000, a high en bloc resection rate allowing pathological assessment of margin and depth has become possible. While ER is a diagnostic method of treatment and may not always be curative, it is widely accepted as standard treatment because it is less invasive than surgery and can provide an accurate diagnosis for deciding whether additional surgery is necessary. The curability of ER is currently assessed by the completeness of primary tumor removal and the possibility of lymph node metastasis. This review introduces methods, indications, and curability criteria for ER of EGC. Despite recent advances, several problems remain unsolved. This review will also outline the latest evidence concerning future issues.

30 November 2025 in Clinical Endoscopy
Verified
Journal Article
Open access
THTakuma Hiramatsu
Takuma Hiramatsu
NKNaomi Kakushima
Naomi Kakushima
HKHikaru Kuribara
Hikaru Kuribara
RMRyohei Miyata
Ryohei Miyata
HNHideki Nakagawa
Hideki Nakagawa
MFMitsuhiro Fujishiro
Mitsuhiro Fujishiro
Approximately 90% of cases of gastric cancer (GC) are caused by Helicobacter pylori infection, and screening esophagogastroduodenoscopy is effective for secondary prevention of GC. Endoscopic findings of the stomach due to H. pylori infection vary widely, and the risk of GC varies according to each finding. GC risk is evaluated by combining endoscopic and histopathological findings. In the operative link on gastritis assessment and operative link on gastric intestinal metaplasia assessment staging, GC risk is determined by histopathological evaluation. In the endoscopic grading of gastric intestinal metaplasia, Kyoto classification, and modified Kyoto classification, the risk is considered based on endoscopic findings. However, evaluating endoscopic findings is challenging because the evaluation varies depending on the skill of the endoscopist. Similarly, histopathological findings can be assessed differently by different pathologists. Histopathological evaluation by biopsy carries a risk of bleeding; thus, simpler and less-invasive risk stratification methods are desirable. Artificial intelligence for risk stratification, which has the potential for improved accuracy and consistency, has been developed for endoscopic and histopathological evaluations. Appropriate GC risk stratification would benefit the economy and patients, and further evaluation of surveillance intervals tailored to individual risks is warranted.

28 March 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
SMSatoru Mizutani
Satoru Mizutani
YTYu Takahashi
Yu Takahashi
TSTakeshi Shimamoto
Takeshi Shimamoto
HNHideki Nakagawa
Hideki Nakagawa
HHHiroyuki Hisada
Hiroyuki Hisada
MFMitsuhiro Fujishiro
Mitsuhiro Fujishiro
The ABC method is a classification method used for stratifying the risk of gastric cancer. However, whether the ABC method should be performed only once or multiple times throughout an individual’s lifetime remains unclear. Therefore, this study aimed to analyze whether performing ABC screening twice in a lifetime is useful. We retrospectively analyzed the data of individuals who participated in health checkups in 2010 and 2015. We collected data on patient characteristics, pepsinogen levels, anti-Helicobacter pylori antibody titers, and the presence of gastric cancer. Overall, 7129 participants without a history of H. pylori eradication were included in this study. The participants’ average age in 2010 was 48.4 ± 8.3 years, and 58.1% were male. In addition, 11 and 20 cases of new H. pylori infection (0.15%) and spontaneous eradication (0.28%), respectively, were recorded. No significant difference was found in the incidence of gastric cancer between participants who underwent the ABC method once and those who underwent it twice (Group A: 0.16% vs. 0.16%; Group B: 0.47% vs. 0.39%; and Group C + D: 1.97% vs. 1.82%). Therefore, performing the ABC method twice, 5 years apart, does not significantly improve gastric cancer risk stratification.

21 December 2021 in Endoscopy
Verified
Journal Article
Closed access
PDF file
DKDai Kubota
Dai Kubota
YSYoshiki Sakaguchi
Yoshiki Sakaguchi
SNSayaka Nagao
Sayaka Nagao
YTYosuke Tsuji
Yosuke Tsuji
MFMitsuhiro Fujishiro
Mitsuhiro Fujishiro
A 73-year-old man was referred to our department with a diagnosis of esophageal adenocarcinoma (EAC) in long-segment Barrett’s esophagus (BE), Prague classification C12M14. The long-segment BE extended to the upper thoracic esophagus and non-detectable adenocarcinoma was confirmed in multiple areas of the long-segment BE by random biopsies ([Fig. 1]). Esophageal endoscopic submucosal dissection (ESD) of the entire area of long-segment BE was therefore performed, with the patient under general anesthesia ([Video 1]). The lesion was resected en bloc ([Fig. 2]), in 220 minutes, with no adverse events. The total circumferential wound was 16 cm in length, and steroid injection and polyglycolic acid shielding were performed to prevent stenosis [1]. Histological assessment showed a curative resection, with adenocarcinoma invasion limited to the superficial muscularis mucosa, no lymphovascular invasion, and tumor-free margins ([Fig. 3]). After the patient’s discharge, local steroid injections were performed periodically. Squamous epithelium regeneration was found in the post-ESD area 6 months after ESD, with no recurrence of BE, and no evidence of stenosis ([Fig. 4]). Video 1 Subtotal esophageal endoscopic submucosal dissection is performed to treat long-segment Barrett’s esophagus and adenocarcinoma. Currently, radiofrequency ablation, cryotherapy, or hybrid argon plasma coagulation after endoscopic resection are recommended as treatment methods for BE, including where high grade dysplasia is present [2]; intraepithelial carcinoma has also been reported to be controllable by these methods. On the other hand, there is a risk of buried BE due to remnant BE after these endoscopic therapies [3]. In this case, ESD not only resulted in curative treatment of the EAC, confirmable by histologic assessment following R0 resection, but also resulted in complete en bloc resection of the BE, with no risk of remnant BE. Recent advances in endoscopic technology, resection methods, and the development of effective methods of prophylactic treatment for adverse events have enabled safe and effective extensive esophageal ESD [4] [5]. Curative treatment with just one session of ESD may become a new standard for treatment of EAC in BE. Endoscopy_UCTN_Code_TTT_1AO_2AG Publication Date: 21 December 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany